In the past week, TEVA stock has gone up by 0.99%, with a monthly gain of 5.32% and a quarterly surge of 30.97%. The volatility ratio for the week is 2.44%, and the volatility levels for the last 30 days are 2.40% for Teva- Pharmaceutical Industries Ltd. ADR. The simple moving average for the past 20 days is 3.60% for TEVA’s stock, with a 37.84% simple moving average for the past 200 days.
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
Company’s 36-month beta value is 1.06.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 17 as “hold,” and 5 as “sell.”
The public float for TEVA is 1.12B, and currently, short sellers hold a 0.93% ratio of that floaft. The average trading volume of TEVA on April 08, 2024 was 10.73M shares.
TEVA) stock’s latest price update
The stock of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) has increased by 2.30 when compared to last closing price of 13.93.Despite this, the company has seen a gain of 0.99% in its stock price over the last five trading days. Reuters reported 2024-04-01 that Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with JP Morgan repeating the rating for TEVA by listing it as a “Neutral.” The predicted price for TEVA in the upcoming period, according to JP Morgan is $14 based on the research report published on March 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $19, previously predicting the price at $12. The rating they have provided for TEVA stocks is “Overweight” according to the report published on February 12th, 2024.
Jefferies gave a rating of “Buy” to TEVA, setting the target price at $14 in the report published on January 23rd of the current year.
TEVA Trading at 8.59% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.38% of loss for the given period.
Volatility was left at 2.40%, however, over the last 30 days, the volatility rate increased by 2.44%, as shares surge +3.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.05% upper at present.
During the last 5 trading sessions, TEVA rose by +0.99%, which changed the moving average for the period of 200-days by +88.74% in comparison to the 20-day moving average, which settled at $13.78. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw 36.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Kalif Eliyahu Sharon, who sale 77,550 shares at the price of $13.52 back on Mar 06 ’24. After this action, Kalif Eliyahu Sharon now owns 203,691 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,048,119 using the latest closing price.
Sabag Mark, the EVP, International Markets of Teva- Pharmaceutical Industries Ltd. ADR, sale 100,000 shares at $13.52 during a trade that took place back on Mar 05 ’24, which means that Sabag Mark is holding 382,590 shares at $1,352,090 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.48 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.04. The total capital return value is set at 0.03. Equity return is now at value -6.84, with -1.20 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 2.68. The interest coverage ratio of the stock is 0.91.
Currently, EBITDA for the company is 4.27 billion with net debt to EBITDA at 3.95. When we switch over and look at the enterprise to sales, we see a ratio of 2.08. The receivables turnover for the company is 4.65for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.02.
Conclusion
In a nutshell, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has experienced a better performance in recent times. The stock has received mixed “sell” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
